Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by TheEconomyon Mar 06, 2021 3:47pm
303 Views
Post# 32736896

RE:RE:RE:RE:RE:RE:JAMA Cardiology Study

RE:RE:RE:RE:RE:RE:JAMA Cardiology StudyExactly, good call. If you're not invested in the company, or considering being invested, there is no reason to be here. Unless of course, you're being rewarded to spread doubt. Many companies valuations do not match their share price, this is not rocket science. You factor in "possibility and chance" and weigh it against "market conditions and sector comparables" and come up with market value. Right now you could make the argument vpt is worth $12 per share or $.12 per share, it's up to the individual investor to determine what they believe. G-Bomb wants you to only focus on the bottom and that is why he's a D-Bag. 
<< Previous
Bullboard Posts
Next >>